Drug Trial Radar · NCT07933328
Study to Evaluate ALN-CIDEB in Adults With Fibrotic Alcohol-Associated Liver Disease (ALD)
Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
120
Planned (sponsor's estimate)
Start
Dec 9, 2026
Primary completion
May 7, 2029
Study completion Jul 28, 2029
Sponsor
- Lead sponsor
- Regeneron PharmaceuticalsRegeneron (REGN)
- Sponsor type
- Industry
- First posted
- Nov 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called alcohol-associated liver disease (ALD). ALD is a type of liver disease caused by drinking alcohol at levels that are harmful to the body. The study will also test ALN-CIDEB in participants who are known to have metabolic dysfunction- and alcohol- associated liver disease (MetALD), a subgroup of people that have features of both ALD and metabolic dysfunction-associated steatotic liver disease (MASLD). The study will compare 2 different dose regimens of ALN-CIDEB with placebo (something that looks like the study drug but doesn't contain any medicine) to understand how well ALN-CIDEB works to lower the amount of fat in the liver. The study is looking at: * What side effects ALN-CIDEB might cause * How well ALN-CIDEB works to change liver fat and stiffness of the liver * How ALN-CIDEB could affect the liver proteins
Conditions
- Alcohol-Associated Liver Disease
- ALD
Interventions
ALN-CIDEBDrug
Administered per the protocol
PlaceboDrug
Administered per the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change from Baseline in Liver Fat by Magnetic Resonance Imaging-Proton Density Fat fraction (MRI-PDFF)Time frame: At Week 52
- Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Through Week 64
- Severity of TEAEsTime frame: Through Week 64
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.